ImClone, Round 2: One Hit, One Miss

A House panel's second hearing on the biotech turns up new dirt on CEO Waksal -- but makes little progress toward FDA reforms

By Catherine Arnst

To continue reading this article you must be a Bloomberg Professional Service Subscriber.